Office of the Director, National Institutes of Health; Notice of Meeting, 50516 [2012-20556]

Agencies

• DEPARTMENT OF HEALTH AND HUMAN SERVICES
• National Institutes of Health

[Federal Register Volume 77, Number 162 (Tuesday, August 21, 2012)]
[Notices]
[Page 50516]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-20556]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: September 12, 2012.
    Time: 2:00 p.m. to 5:00 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
discuss selected human gene transfer protocols. Please view the 
meeting agenda at https://oba.od.nih.gov/rdna_rac/rac_meetings.html 
for more information.
    Place: Hilton Washington/Rockville, 1750 Rockville Pike, 
Rockville, MD 20852.
    Contact Person: Chezelle George, Office of Biotechnology 
Activities, Office of Science Policy/OD, National Institutes of 
Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-
9838, georgec@od.nih.gov.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    OBA will again offer those members of the public viewing the 
meeting via webcast (see OBA Meetings Page available at the 
following URL: https://oba.od.nih.gov/rdna_rac/rac_meetings.html) 
to submit comments during the public comment periods. Individuals 
wishing to submit comments should use the comment form, which will 
accommodate comments up to 1500 characters, and will be available on 
the OBA web site during the meeting (see OBA Meetings Page). Please 
limit your comment to a statement that can be read in one to two 
minutes. Please include your name and affiliation with your comment. 
Only comments submitted through the OBA Web site will be read.
    OBA will read comments into the record during the public comment 
periods as stated on the agenda. It is not unusual for the meeting 
to run ahead or behind schedule due to changes in the time needed to 
review a protocol. It is advisable to monitor the webcast to 
determine when public comments will be read. Each public comment 
period follows a specific discussion item. OBA will read comments 
that are related to the protocol or presentation under discussion at 
that time. General comments unrelated to a specific agenda item will 
be read at the end of the meeting, time permitting. Comments 
submitted by email through the OBA Web site will follow any comments 
by individuals attending the meeting. Comments will be read in the 
order received and your name and affiliation will be read with the 
comments. Please note OBA may not be able to read every comment 
received in the time allotted for public comment. Comments not read 
will become part of the public record.
    Information is also available on the Institute's/Center's home 
page: https://oba.od.nih.gov/rdna/rdna.html, where an agenda and any 
additional information for the meeting will be posted when 
available. OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: August 14, 2012.
Anna Snouffer,
Deputy Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-20556 Filed 8-20-12; 8:45 am]
BILLING CODE 4140-01-P